Cempra $CEMP nosedived more than 35% amid heavy trading volume in response to the FDA briefing document for Friday�s AD Comm. review of SOLITHROMYCIN. On page 34, it has been stated that these clinical findings comprise a �genuine liver injury signal, adding �the likelihood of serious idiosyncratic hepatic liver injury in a larger population and the impact of prior sensitization to macrolides on solithromycin-induced liver injury are unknown,� � an observation which implicitly states that there is a need of additional clinical trials.